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ABSTRACT 
Aims: A higher body mass index (BMI) is associated with better survival in heart failure (HF) 
patients, also known as the obesity paradox. However, BMI does not account for body composition. 
We therefore analysed the association between abdominal fat, measured via waist-hip ratio (WHR), 
BMI and all-cause mortality in patients with HF. 
Methods: For this analysis 1738 patients from The Scottish BIOlogy Study to TAilored Treatment in 
Chronic Heart Failure (BIOSTAT-CHF) validation study were included. Patients without waist and 
hip measurements were excluded. WHR was defined as waist circumference/hip circumference, 
divided into tertiles and split for sex. A linear regression of principal components from an extensive 
panel of biomarkers was performed to provide insight in the pathophysiology behind a higher WHR. 
Results: In total, 1479 patients with were included, of which 33% were female and mean age was 
75±11 years. A higher WHR was independently associated with a higher BMI, a higher prevalence of 
diabetes and higher functional NYHA class. There was a significant interaction between sex and WHR 
on its association with mortality (P<0.001). In women, a higher WHR was associated with a higher 
mortality risk (HR 2.01; 95% confidence interval (CI) 1.33-3.02, P=0.001), whereas no significant 
association was found in men (HR 1.21, 95% CI 0.87-1.69, P=0.262). We found a strong association 
between a higher WHR and elevated markers of inflammation and MAPK cascade in women, while in 
men these associations were less profound. 
Conclusions: A higher WHR was associated with a higher risk of death in female, but not in male HF 
patients. These findings challenge the obesity paradox, and suggest that fat deposition is 
pathophysiologically harmful and may be a target for therapy in female patients with HF.  
Keywords: heart failure, obesity, waist-hip ratio, body mass index, mortality 
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INTRODUCTION 
Obesity a risk factor for the development of heart failure (HF), but in patients with established HF a 
higher body mass index (BMI) is associated with a lower risk of death.(1-4) This so-called obesity 
paradox describes improved survival rates in HF patients, with a BMI between 25-35 kg/m2 compared 
with normal or underweight HF patients. Although this paradox has been widely described, the precise 
mechanisms behind this paradox are not well understood. The most commonly used measurement to 
define obesity is BMI. However, patients with a high BMI might be misclassified as HF due to 
dyspnoea, and BMI fails to account for body composition, including fat distribution and fluid in the 
third space. Specifically, BMI may neglect the effects of abdominal fat, which has been identified as a 
potential risk factor in the onset of HF and is known to be associated with mortality in the general 
population.(5-7) Abdominal fat is better reflected by measuring waist to hip ratio (WHR). However, 
nothing is known about the association between WHR and clinical outcome in patients with 
established HF. We therefore examined the association between abdominal fat, measured via WHR, 
BMI and all-cause mortality.  
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METHODS 
Study population 
For the current analysis, we used data from BIOSTAT-CHF (A systems BIOlogy Study to Tailored 
Treatment in Chronic Heart Failure). BIOSTAT-CHF is a multicentre, prospective observational 
study.(8-10) For this study, the BIOSTAT-CHF cohort from Scotland was used, since only in this 
cohort WHR was routinely measured (n=1738). Main inclusion criteria were documented HF and 
patients had to be treated with at least 20mg furosemide or equivalent per day and were anticipated to 
be up titrated with ACE inhibitors/ARBs and/or beta-blockers. The complete list of inclusion and 
exclusion criteria has been previously published elsewhere.(8) The study complied with the 
Declaration of Helsinki, local ethics committee has approved the research protocol and all patients 
signed informed consent . WHR was calculated as waist circumference (WC) divided by hip 
circumference (HC). WC and hip circumference (HC) were measured according to the World Health 
Organization (WHO) recommendations. The subject was asked to stand relaxed with arms at the sides, 
feet positioned close together and weight evenly distributed across feet. WC was measured midway 
between the lowest rib and the superior border of iliac crest. HC was measured at the level of widest 
portion of buttocks (trochanters). All measurements were in centimetres (cm) to the nearest 0.1 cm. 
Body mass index was calculated as weight in kilograms (kg) divided by squared length in meters (m). 
Obesity based on both BMI (≥30 kg/m2) and WHR (for men ≥0.90, for women ≥0.85) was defined 
according to the World Health Organisation guidelines. Patients were divided into sex specific tertiles 
of WHR, since fat metabolism and deposition differs with sex. HF with reduced ejection fraction was 
defined as an left ventricular ejection fraction (LVEF) <40%, HF with mid-range ejection fraction as a 
LVEF between 40 and 50% and HF with preserved ejection fraction as a LVEF equal or above 50%, 
according to the most recent ESC HF guidelines.(11)  
Laboratory analysis 
Additional analyses were performed using a high-throughput technique using the Olink Proseek® 
Multiplex INF I96 96 kit, which measures 92 selected cardiovascular-related proteins simultaneously 
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in 1μl plasma samples.(12) The amplicons are subsequently quantified using a Fluidigm BioMark™ 
HD real-time PCR platform. The platform provides normalized protein expression (NPX) data where a 
high protein value corresponds to a high protein concentration, but not an absolute quantification. 
These proteins were divided by Olink into thirteen domains; Inflammation, Catabolic process, 
Angiogenesis/blood vessel morphogenesis, Cell adhesion, Chemotaxis, Coagulation, mitogen-
activated protein kinase (MAPK) cascade, Platelet activation, Proteolysis, Hypoxia, Response to 
peptide hormone, Wound healing and other (Supplementary Table 1). The manufacturer of the protein 
assay, Olink Bioscience (Uppsala, Sweden), had no input on the study design, analysis or manuscript 
preparation. 
Statistical analysis 
Normally distributed data is shown as means and standard deviation, whereas not normally distributed 
data as medians and 25th until 75th percentile, and categorical variables as percentages and frequencies. 
Differences between variables were tested using one-way ANOVA for normal distributed data; 
skewed data was tested using Chi-squared test or Kruskal-Wallis test when appropriate. Linear 
regression was performed to assess associated variables with WHR and BMI. Univariable significant 
variables (P<0.1) were entered in a multivariable backward selection. The final backward 
multivariable model contained demographics, clinical variables and laboratory measurements. All 
non-normally distributed variables were transformed accordingly prior to adding them to the 
multivariable models. Kaplan-Meier curves were drafted to show differences in survival between 
tertiles of WHR groups. Cox proportional hazard analysis was performed to determine hazard ratios 
for the different groups. Restricted cubic splines were used to explore the functional association 
between WHR on a continuous level and all-cause mortality. Results were summarized by adjusted 
hazard ratios of the general model (solid line), and confidence intervals based on restricted cubic 
splines. To assess an independent contribution, all multivariable models were adjusted for a previously 
published prognostic model within BIOSTAT-CHF, BMI when appropriate for the use of statins, and 
sex-specific confounders.(13) When WHR is corrected for BMI it has been shown to be a proper 
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surrogate measurement of abdominal obesity. (14) 
To assess each of the pathophysiological domains with WHR, principal component analysis was 
performed with the markers in each disease domain. The first principal component was used as a linear 
variable and the association with WHR was univariably assessed with a linear regression and the 
standardized betas were plotted. P-values were corrected for multiple testing by dividing 0.05 by the 
number of biomarkers within each of the domains. Interaction between sex and WHR on the risk of 
death was assessed by modelling WHR on a continuous scale.  
All analyses were performed using IBM SPSS Statistics version 23 and R: a Language and 
Environment for Statistical Computing, version 3.4.2. (R Foundation for Statistical Computing, 
Vienna, Austria). 
RESULTS 
Baseline characteristics 
Patients with measured WHR were included (n=1479), of which 997 were men (67%) and 482 women 
(33%). Baseline characteristics are depicted in Table 1. Mean WHR in women was 0.93±0.09, and 
mean WHR in men was 1.00±0.08. 
Associates of WHR and BMI 
Table 2 shows the associates of WHR or BMI in women and men. In both women and men a higher 
WHR was associated with a higher body weight (P=0.001 and P<0.003 respectively), higher glucose 
levels (P=0.004 and P=0.001 respectively) and lower serum iron levels (P=0.021 and P=0.020 
respectively). In women a higher WHR was also associated with less use of betablocker (β=-0.130, 
P=0.018) and higher NT-proBNP (β=0.156, P=0.007). In men a higher WHR was also associated with 
a lower height (β=-0.104, P=0.006) and a higher age (β=0.073, P=0.046). 
BMI was in both women and men associated with higher waist and hip circumference, lower NT-
proBNP levels, lower age, and more edema. In women the only other variable associated with a higher 
BMI was a history of hypertension (β=0.103, P=0.003). In men, variables associated with a higher 
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BMI were a higher diastolic blood pressure (β=0.055, P=0.033), higher TSH levels (β=0.051, 
P=0.045) and the presence of diabetes (β=0.051, P=0.050). 
Biomarkers associated with WHR 
Standardized betas of the principal components of the different domains and WHR were plotted in 
Figure 1. In women the strongest associations of WHR were found with inflammation (β = 0.181, 
P<0.001) and MAPK cascade (β = 0.162, P<0.001), while in men these associations were less 
profound and non-significant after correction for multiple testing (β = 0.081, P=0.011 and β = 0.082, 
P=0.010 respectively).  
Mortality 
We found a significant interaction between sex and WHR on the risk of death (P for 
interaction<0.001).  
During a median follow-up of 21 months, 34% of women had died, ranging from 22% in the lowest 
tertile to 45% in the highest WHR tertile (P<0.001). As shown in Figure 2, women with a BMI < 30 
kg/m2 had higher mortality rates compared to women with a BMI > 30 kg/m2 (P=0.042). However, 
women with a WHR below the mean had a significantly better survival (P<0.001). In women, patients 
in the highest WHR tertile had a significantly higher multivariable adjusted risk of death compared to 
women in the lowest WHR tertile, as seen in Table 3 (Hazard ratio (HR) 2.23, [95% Confidence 
interval (CI) 1.37-3.63], P=0.001). The HR was plotted on a continuous scale in Figure 3. For women, 
a linear increase of HR was seen with an increasing WHR. 
During a median follow up of 21 months, 33% of the male patients had died, ranging from 31% in the 
lowest WHR tertile to 37% in the highest WHR tertile. There was no significant difference in a WHR 
above or below the mean (P=0.059). Furthermore, there was no significant difference in HR between 
the WHR tertiles in men (Table 3). 
Supplementary Figure 2 shows the HR for all-cause mortality within HF with reduced ejection 
fraction (HFrEF), HF with mid-range ejection fraction (HFmrEF) and HF with preserved ejection 
8 
 
fraction (HFpEF). There was no significant interaction found between LVEF on a continuous scale 
and WHR, or between HF category and WHR. Separate data on waist circumference alone and hip 
circumference alone in women and men is depicted in Supplementary Figure 3.  
 
 
DISCUSSION 
This is the first study to show an association between a higher WHR, reflecting abdominal obesity, 
and an increased risk of death in female patients with HF, but not in male patients. Patients with a 
lower BMI and a higher WHR had the highest all-cause mortality risks in both women and men. 
Waist-hip ratio, BMI and mortality 
We found a significant interaction between sex and the association of WHR and the risk of death. The 
complex relationship between fat distribution and outcome has been an on-going topic throughout the 
past years, where a recent study has even hinted that patients with a higher waist circumference might 
benefit more from eplerenone treatment.(15) Koster et al. have recently shown that in men 
intermuscular fat was associated with higher mortality, while in woman visceral fat was associated 
with increased mortality risks.(16) Adipose tissue is known to be a secreting organ of multiple 
adipokines. Gluteofemoral fat is known to secrete more favourable adipokines and thus can be 
associated with better outcome, while visceral fat is known to be associated with a worse 
outcome.(17,18) One of the explanations for the difference seen in women and men in our study could 
be that fat distributes differently in both sexes. While men are known to accumulate more visceral fat, 
and therefore have a higher WHR, women often store fat subcutaneously in the gluteofemoral 
region.(19) If WHR increases substantially in women, this might therefore supersede the beneficial 
effects of subcutaneous fat and significantly increase mortality rates. We also found a higher WHR in 
women to be more strongly associated with markers of inflammation and MAPK cascade. As is 
known, the MAPK cascade is often involved in cardiac remodelling and vascular disease.(20) A 
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variety of different cascades play a role in hypertrophy and pathological remodelling, and are known 
to be associated with worse outcomes.(21) The same holds true for the process of inflammation, which 
is known to be associated with HF, especially HFpEF.(22,23) Inflammation is also known to be 
associated with adverse cardiac remodelling, and worse outcome in HF.(24) The stronger associations 
within women with a higher WHR and these processes might (partially) explain the worse outcome we 
found in women. 
Obesity paradox 
Several studies have previously shown that patients with HF and with higher BMI levels had a lower 
mortality risk compared to HF patients with normal of a low BMI.(4,25) There are however multiple 
limitations on the use of BMI as a measurement for obesity. BMI does not provide an indication of the 
fat distribution in the body, and could also be raised with more decompensated HF patients due to 
fluid accumulation. Furthermore, BMI has the limitation that it does not differ between fat and muscle 
mass, and therefore might not differ between fitness and fatness. In a recent analysis, Piepoli et al. 
have shown that exercise tolerance matters, and after correction for cardiorespiratory fitness the 
protective effect of BMI disappeared.(26)  
Previous studies using solely waist circumference as a measurement of abdominal obesity showed 
contradicting results with our study, where in patients with HFrEF a higher waist circumference was 
associated with lower mortality rates Tsujimoto et al found a higher waist circumference in patients 
with HFpEF to be associated with higher mortality rates in a multivariable analysis.(6,27,28) Part of 
the difference could be explained by the fact that we used WHR instead of waist circumference alone. 
When assessing WHR, not only waist circumference is used, but by using WHR one might 
discriminate more accurately between abdominal fat (large waist circumference, normal/small hip 
circumference) and merely a larger body size (large waist circumference and large hip circumference). 
In the present study, we showed that fat distribution matters, where an increase in WHR in patients 
with HF is associated with a gradual increase in risk of death, and that this was more pronounced in 
women.  
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The risk associated with abdominal obesity in the general population was previously shown in a paper 
by Pischon et al., which showed a U-shaped risk for mortality with BMI, but abdominal obesity was 
associated with an increasing mortality risk.(29) Although the underlying mechanisms are unknown, 
one can speculate about possible contributing factors. A high WHR is known to be associated with a 
high burden of atherosclerosis, where the association between BMI and atherosclerosis is less 
pronounced. Therefore central obesity might play a role in the initiation and progress of 
atherosclerosis.(30) Although this might hold true for the general population, it was unknown whether 
the same risk was associated with mortality in patients with HF. 
 
Metabolic syndrome 
We showed a higher prevalence of diabetes mellitus, higher glucose levels and lower HDL cholesterol 
with increasing WHR. A higher WHR is known to be associated and incorporated within the definition 
of the metabolic syndrome.(31,32) This syndrome consists of multiple factors, some of which are 
associated with increased survival (such as obesity), or are known to worsen onset and/or progression 
of HF.(33,34) Most likely the metabolic syndrome induces a pro-inflammatory state, where abdominal 
adiposity plays a pivotal role. Consistent with these results, we found higher levels of inflammatory 
markers in the upper tertiles of WHR. An altered balance in adipokines and increasing insulin 
resistance are most likely responsible for the association with worse outcome for patients with 
metabolic syndrome, together with accompanying comorbidities such as hypertension and 
dyslipidaemia.(35) Besides these systemic effects of central adiposity, there is also an association with 
adverse cardiac mechanisms such as worse global longitudinal strain and early diastolic strain rate. 
This association was found for both abdominal obesity and WHR.(36,37) To the best of our 
knowledge, we are the first to show this increased risk for female patients and a higher WHR in a HF 
population.  
Strengths and limitations 
This study is limited by its retrospective nature. Secondly, in patients with HF and a large abdominal 
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mass, it is difficult to distinguish between fat and fluid. Thirdly, WHR measurements were performed 
by different individuals, although they were provided with clear instructions.  
 
CONCLUSION 
A higher WHR was associated with higher mortality in female, but not in male HF patients. This 
might be explained by a higher inflammatory status with a higher WHR in woman, but not in men. 
This association was independent of BMI. These findings challenge the obesity paradox, and suggest 
that abdominal fat deposition is pathophysiologically harmful and maybe a target for therapy in 
(female) patients with HF. 
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Table 1; Baseline characteristics 
Sex  Women    Men   
Waist-hip-ratio  1st tertile 2nd tertile 3rd tertile P-value 1st tertile 2nd tertile 3rd tertile P-value 
N = 171 151 160  360 282 355  
Waist-hip-ratio 0.84±0.05 0.93±0.02 1.02±0.05 <0.001 0.92±0.04 0.99±0.02 1.08±0.07 <0.001 
Age (years) 76±11 77±11 77±11 0.539 75±11 76±10 75±10 0.856 
Systolic Blood Pressure (mmHg) 125±22 129±26 125±24 0.207 126±21 125±22 126±22 0.689 
Diastolic Blood Pressure (mmHg) 68±13 67±15 68±14 0.558 71±12 68±11 71±13 0.039 
Heart Rate (beats/min) 73±15 75±16 78±17 0.009 72±16 72±17 73±15 0.739 
Clinical profile         
LVEF (%) 43±13 43±14 44±13 0.695 39±13 40±11 39±12 0.865 
HFrEF (%) 61 (39) 62 (44) 53 (37) 0.659 169 (51) 135 (51) 182 (55) 0.130 
HFmrEF (%) 43 (27) 30 (21) 36 (25)  89 (27) 81 (30) 71 (21)  
HFpEF (%) 53 (34) 49 (35) 54 (38)  71 (22) 51 (19) 80 (24)  
Peripheral edema present (%) 89 (59) 95 (66) 107 (74) 0.020 155 (48) 158 (63) 203 (61) <0.001 
Rales present (%) 51 (32) 67 (46) 85 (54) 0.001 122 (36) 116 (43) 149 (43) 0.103 
Elevated JVP (%) 38 (26) 46 (34) 37 (26) 0.255 90 (29) 82 (32) 90 (29) 0.629 
Height (cm) 159±7 159±7 158±8 0.489 173±8 173±8 173±9 0.579 
Weight (kg) 68.8±18.2 76.2±18.2 75.2±17.8 <0.001 80.3±15.6 86.1±17.6 92.4±20.9 <0.001 
Body mass index (kg/m2) 
25.7 
 [22.9-30.8] 
29.6 
[25.1-33.7] 
29.6 
[25.2-35.2] <0.001 
26.2 
 [23.5-29.7] 
28.8 
[25.1-31.8] 
30.7 
[26.5-34.4] <0.001 
Medical History         
Hypertension (%) 95 (56) 92 (61) 102 (64) 0.360 188 (52) 150 (53) 222 (63) 0.010 
Myocardial Infarction (%) 71 (42) 49 (33) 73 (46) 0.053 180 (50) 163 (58) 191 (54) 0.130 
PCI (%) 24 (14) 27 (18) 31 (19) 0.409 69 (19) 72 (26) 55 (16) 0.006 
CABG (%) 15 (9) 12 (8) 15 (9) 0.905 75 (21) 65 (23) 81 (23) 0.759 
Diabetes mellitus (%) 40 (23) 43 (29) 58 (37) 0.033 92 (26) 82 (29) 153 (43) <0.001 
Stroke (%) 28 (17) 22 (15) 32 (20) 0.448 66 (18) 44 (16) 72 (21) 0.321 
Atrial Fibrillation (%) 74 (44) 54 (36) 65 (41) 0.363 177 (50) 124 (44) 160 (45) 0.307 
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Sex  Women    Men   
Waist-hip-ratio  1st tertile 2nd tertile 3rd tertile P-value 1st tertile 2nd tertile 3rd tertile P-value 
N = 171 151 160  360 282 355  
COPD (%) 29 (17) 27 (18) 41 (26) 0.110 57 (16) 48 (17) 60 (17) 0.891 
Peripheral arterial disease (%) 28 (17) 40 (27) 35 (23) 0.070 79 (23) 73 (26) 78 (23) 0.484 
NYHA Class    <0.001    <0.001 
1 1 (0.6) 0 (0) 0 (0)  8 (2.2) 1 (0.4) 5 (1.4)  
2 83 (48.5) 48 (32.0) 43 (26.9)  200 (55.6) 127 (45.0) 139 (39.2)  
3 69 (40.4) 74 (49.3) 74 (46.3)  129 (35.8) 130 (46.1) 160 (45.1)  
4 18 (10.5) 28 (18.7) 43 (26.9)  23 (6.4) 24 (8.5) 51 (14.4)  
Beta blocker (%) 122 (71) 97 (64) 104 (65) 0.321 277 (77) 212 (75) 260 (73) 0.519 
MRA (%) 52 (30) 51 (34) 46 (29) 0.622 115 (32) 91 (32) 119 (34) 0.895 
Diuretics (%) 170 (99) 149 (99) 156 (98) 0.342 353 (98) 280 (99) 352 (99) 0.269 
ACE-i/ARB (%) 130 (76) 97 (64) 102 (64) 0.025 269 (75) 209 (74) 258 (73) 0.817 
Statins (%) 95 (56) 87 (58) 97 (61) 0.645 218 (61) 187 (66) 232 (65) 0.249 
Laboratory values         
Glucose (mmol/L) 5.5 [4.8-7.0] 6.1 [5.1-8.1] 6.7 [5.7-8.7] <0.001 5.8 [5.0-7.3] 6.2 [5.3-8.3] 6.8 [5.6-10.2] <0.001 
HDL cholesterol 
1.32  
[1.03-1.64] 
1.25  
[1.03-1.53] 
1.20 
[0.96-1.49] 0.211 
1.08  
[0.89-1.37] 
1.05  
[0.85-1.28] 
1.02 
[0.84-1.22] 0.002 
NT-proBNP (ng/L) 
1027 
[383-2594] 
1142 
[364-2907] 
1758 
[528-4953] 0.029 
1391 
[554-3177] 
1299 
[508-2937] 
1240 
[486-3289] 0.665 
FABP4 
6.04 
[5.36-6.79] 
6.45 
[5.72-7.53] 
6.57 
[5.68-7.38] <0.001 
5.37 
[4.75-6.12] 
5.65 
[4.98-6.32] 
5.88 
[5.23-6.74] <0.001 
TNF-R1 
5.32 
[4.92-5.88] 
5.54 
[5.01-6.12] 
5.56 
[5.09-6.06] 0.015 
5.29 
[4.89-5.73] 
5.40 
[5.01-5.89] 
5.46 
[5.02-6.15] <0.001 
Outcome         
All-cause mortality (%) 38 (22.2) 47 (31.3) 72 (45.0) <0.001 112 (31.1) 92 (32.9) 130 (36.9) 0.245 
Hospitalization (%) 50 (29.4) 69 (46.0) 73 (45.6) 0.002 131 (36.4) 82 (29.3) 136 (38.7) 0.040 
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Values are given as means ± standard deviation, median (25th to 75th percentiles) or percentage and frequency 
LVEF = Left ventricular ejection fraction; HFrEF = Heart failure with reduced ejection fraction; HFmrEF = Heart failure with mid-range ejection fraction; HFpEF = Heart failure with preserved ejection fraction; JVP = Jugular venous pressure; PCI = Percutaneous 
coronary intervention; CABG = Coronary artery bypass surgery; COPD = Chronic obstructive pulmonary disease; NYHA = New York Heart Association; MRA = Mineralocorticoid receptor antagonist; ACE-i/ARB = ACE-inhibitor/Angiotensin II receptor blocker; 
HDL = High density lipoprotein; NT-proBNP = N-terminal pro brain natriuretic peptide; KCCQ = Kansas city Cardiomyopathy Questionnaire; VAS = Visual analog scale 
Table 2; Multivariable linear regression for waist-hip ratio and body mass index 
 
WHR Women R2=0.11  Men R2=0.18  
Variable β t-value p-value β t-value p-value 
Weight 0.170 3.00 0.003 0.426 10.9 <0.001 
Glucose 0.157 2.87 0.004 0.115 3.24 0.001 
NT-proBNP 0.156 2.71 0.007    
Betablocker -0.130 -2.37 0.018    
Iron, serum -0.126 -2.32 0.021 -0.082 -2.33 0.020 
Height    -0.104 -2.76 0.006 
Age    0.073 2.00 0.046 
       
 
BMI Women R2=0.66  Men R2=0.62  
Variable β t-value p-value β t-value p-value 
Waist circumference 0.385 6.43 <0.001 0.447 10.7 <0.001 
Hip circumference 0.366 6.05 <0.001 0.279 6.69 <0.001 
Age -0.136 -3.66 <0.001 -0.109 -4.11 <0.001 
History of hypertension 0.103 2.96 0.003    
Edema 0.095 2.66 0.008 0.052 1.99 0.047 
NT-proBNP -0.080 -2.18 0.030 -0.118 -4.20 <0.001 
Diastolic blood pressure    0.055 2.14 0.033 
TSH    0.051 2.01 0.045 
Diabetes    0.051 1.96 0.050 
       
All univariable significant variables (P<0.1) where entered in a multivariable backward selection. WHR = Waist-hip ratio; BMI = Body mass index; HDL = High density 
lipoprotein; NT-proBNP = N-terminal pro brain natriuretic peptide; TSH = thyroid stimulation hormone 
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Table 3; Hazard ratio for tertiles of Waist-hip ratio and all-cause mortality 
 
All-cause mortality 
Women Hazard ratio° P-value Hazard ratio* P-value 
Waist-hip ratio 1st tertile Ref  Ref  
Waist-hip ratio 2nd tertile 
1.49 
[0.97-2.29] 0.068 
1.11 
[0.66-1.89] 0.692 
Waist-hip ratio 3rd tertile 
2.40 
[1.62-3.56] <0.001 
2.23 
[1.37-3.63] 0.001 
All-cause mortality 
Men Hazard ratio° P-value Hazard ratio˟ P-value 
Waist-hip ratio 1st tertile Ref  Ref  
Waist-hip ratio 2nd tertile 
1.12  
[0.85-1.48] 0.419 
0.92  
[0.66-1.27] 0.596 
Waist-hip ratio 3rd tertile 
1.24 
[0.97-1.60] 0.091 
0.87 
[0.63-1.20] 0.409 
 
° Univariable model 
* Corrected for age, BMI, Urea, NT-proBNP, hemoglobin, use of beta-blocker, heart rate, presence of 
rales, NYHA class, history of diabetes, ACE/ARB use, glucose, FABP4 and use of statins 
˟ Corrected for age, BMI, Urea, NT-proBNP, hemoglobin, use of beta-blocker, diastolic blood pressure, 
presence of peripheral edema, NYHA class, history of hypertension, history of diabetes, HDL levels, 
glucose, FABP4 and use of statins 
P for interaction <0.001 between sex and waist-hip ratio for all-cause mortality  
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Figure legends: 
 
Figure 1; Linear regression for different domains with Waist-hip ratio in women and men 
 
Figure 2; Kaplan-Meier for obesity based on BMI in women (A) and men (B). At the bottom for waist-hip ratio 
in women (C) and men (D), according to the WHO guidelines 
 
Figure 3; Hazard ratio for Waist-hip ratio on a continuous scale for women and men. All corrected for age, Urea, 
NT-proBNP, hemoglobin, use of beta-blocker, statins and BMI 
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Figure 1; Linear regression for different domains with Waist-hip ratio in women and men *=significant p-
value after correction for multiple testing 
 Figure 2; Kaplan-Meier for obesity based on BMI in women (A) and men (B). At the bottom for waist-hip ratio in women (C) and men (D), split on the population 
mean. 
A B 
C D 
  
Figure 3; Adjusted effect of WHR on hazard ratio for all-cause mortality. Solid line shows estimated 
linear relation of WHR, while the dotted lines are 95% confidence intervals for a more general relation 
using restricted cubic splines. Corrected for age, Urea, NT-proBNP, hemoglobin, use of beta-blocker, 
statins, heart rate, presence of rales, NYHA class, history of diabetes, ACE/ARB use, glucose levels, 
FABP4 and BMI for women. 
Corrected for age, BMI, Urea, NT-proBNP, hemoglobin, use of beta-blocker, diastolic blood pressure, 
presence of peripheral edema, NYHA class, history of hypertension, history of diabetes, HDL levels, 
glucose, FABP4 and use of statins for men. 
Overall P-value within women P<0.001 and men P=0.136 
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SUPPLEMENTARY MATERIAL 
 
Supplementary Table 1; Olink biomarkers and domains 
 
Domain Markers 
Inflammation AZU1, CCL15, CCL16, CCL22, CCL24, CHI3L1, SELE, FABP4, 
ITGB2, IL-1RT1, IL-17RA, IL2-RA, IL6-RA, JAM-A, LTBR, MCP-1, 
OPN, SELP, PGLYRP1, PAI, RARRES2, CD163, ST2, TR-AP, TR, 
TNF-R1, TNF-R2, TNFRSF10C, TNFRSF14, FAS, AXL 
Catabolic process AP-N, CASP-3, CTSD, CTSZ, CHIT1, COL1A1, CD93, EGFR, 
FABP4, KLK6, LDL receptor, MMP-2, MMP-3, MMP-9, TIMP4, 
PRTN3, MPO, PON3, PGLYRP1, PLC, PCSK9, RARRES2, TNF-R2 
Angiogenesis/blood vessel 
morphogenesis 
AP-N, CCL24, CHI3L1, 4EPHB4, ITGB2, MMP-2, MCP-1, NOTCH3, 
PLC, PAI, PDGF subunit A, uPA 
Cell adhesion AZU1, CDH5, CASP-3, ALCAM, COL1A1, CD93, CNTN1, SELE, 
4EPHB4, EGFR, Ep-Cam, Gal-3, Gal-4, IGFBP-2, IGFBP-7, ITGB2, 
ICAM-2, IL2-RA, MCP-1, OPN, SELP, PAI, PECAM-1, PSP-D, 
SPON1, TR-AP, TLT-2, TNFRSF14, FAS, AXL, SHPS-1, uPA, vWF 
Chemotaxis AZU1, CCL15, CCL16, CCL22, CCL24, CXCL16, ALCAM, Gal-3, 
ITGB2, IL6-RA, MCP-1, PAI, PSP-D, RARRES2, uPA 
Coagulation COL1A1, PRTN3, SELP, PAI, PDGF subunit A, TFPI, t-PA, AXL, U-
PAR, uPA, vWF 
MAPK cascade CCL15, CCL16, CCL22, CCL24, CHI3L1, EGFR, GDF-15, IL2-RA, 
IL6-RA, LTBR, MCP-1, OPG, PDGF subunit A, TNF-R2, TNFRSF14, 
FAS 
Platelet activation COL1A1, SELP, PDGF subunit A, AXL, vWF 
Proteolysis AZU1, BLM hydrolase, CPA1, CASP-3, CTSZ, CSTB, KLK6, MMP-
2, MMP-3, MMP-9, TIMP4, PAI, PCSK9, t-PA, TNF-R2, FAS, U-
PAR, uPA 
Hypoxia CASP-3, MMP-2, MCP-1, MB, PDGF subunit A, t-PA, TR, FAS, uPA 
Response to peptide hormone COL1A1, IGFBP-1, TIMP4, MCP-1, PCSK9, RETN, RARRES2, FAS 
Wound healing  CASP-3, COL1A1, IGFBP-1, KLK6, PRTN3, SELP, PAI, PDGF 
subunit A, TFPI, t-PA, AXL, U-PAR, uPA, vWF 
Other CPB1, PI3, GRN, IL-1RT2, IL-18BP, MEPE, NT-proBNP, DLK-1, 
SCGB3A2, TFF3, TNFSF13B 
 
ALCAM = CD166 antigen; AP-N = Aminopeptidase N; AXL = Tyrosine-proteinkinase receptor UFO; AZU1 = Azurocidin; BLM hydrolase = Bleomycin 
hydrolase; CASP-3 = Caspase-3; CCL15 = C-C motif chemokine 15; CCL16 = C-C motif chemokine 16; CCL22 = C-C motif chemokine 22; CCL24 = C-C 
motif chemokine 24; CD163 = Scavenger receptor cysteine-rich type 1 protein m130; CD93 = Complement component C1q receptor; CDH5 = Cadherin-5; 
CHI3L1 = Chitinase-3-like protein 1; CHIT1 = Chitoriosidase-1; CNTN1 = Contactin-1; COL1A1 = Collagen alpha-1 (I) chain; CPA1 = Carboxypeptidase A1; 
CPB1 = Carboxypeptidase B; CSTB = Cystatin-B; CTSD = Cathepsin D; CTSZ = Cathepsin Z; CXCL16 = C-X-C motif chemokine 16; DLK-1 = Protein delta 
homolog 1; EGFR = Epidermal growth factor receptor; Ep-Cam = Epithelial cell adhesion molecule; EPHB4 = Ephrin type-B receptor 4; FABP4 = Fatty acid-
binding protein, adipocyte; FAS = Tumor necrosis factor receptor superfamily member 6; Gal-3 = Galectin-3; Gal-4 = Galectin-4; GDF-15 = 
Growth/differentiation factor 15; GRN = Granulins; ICAM-2 = Intercellular adhesion molecule 2; IGFBP-1 = Insulin-like growth factor-binding protein 1; 
IGFBP-2 = Insulin-like growth factor-binding protein 2; IGFBP-7 = Insulin-like growth factor-binding protein 7; IL-17RA = Interleukin-17 receptor A; IL-18BP 
= Interleukin-18 binding protein; IL-1RT1 = Interleukin-1 receptor type 1; IL-1RT2 = Interleukin-1 receptor type 2; IL2-RA = Interleukin-2 receptor subunit 
Alpha; IL6-RA = Interleukin-6 receptor subunit Alpha; ITGB2 = Integrin beta-2; JAM-A = Junctional adhesion molecule A; KLK6 = Kallikrein-6; LDL receptor 
= Low-density lipoprotein receptor; LTBR = Lympotoxin-beta receptor; MB = Myoglobin; MCP-1 = Monocypte chemotactic protein 1; MEPE = Matrix 
extracellular phosphoglycoprotein; MMP-2 = Matrix metalloproteinase-2; MMP-3 = Matrix metalloproteinase-3; MMP-9 = Matrix metalloproteinase-9; MPO = 
Myeloperoxidase; NOTCH3 = Neurogenic locus notch homolog protein 3; NT-proBNP = N-terminal pro b-type natriuretic peptide; OPG = Osteoprotegerin 
(OPG); OPN = Osteopontin; PAI = Plasminogen activator inhibitor 1; PCSK9 = Proprotein convertase subtillisin/kexin type 9; PDGF subunit A = Platelet-
derived growth factor subunit A; PECAM-1 = Platelet endothelial cell adhesion molecule; PGLYRP1 = Peptidoglycan recognition protein 1; PI3 = Elafin; PLC = 
Perlecan; PON3 = Paraoxnase; PRTN3 = Myeloblastin; PSP-D = Pulmonary surfactant-associated protein D; RARRES2 = Retinoic acid receptor responder 
protein 2; RETN = Resistin; SCGB3A2 = Secretoglobin family 3A member 2; SELE = E-selectin; SELP = P-selectin; SHPS-1 = Tyrosine-protein phosphatase 
non-receptor type substrate 1; SPON1 = Spondin-1; ST2 = ST2 protein; TFF3 = Trefoil factor 3; TFPI = Tissue factor pathway inhibitor; TIMP4 = 
Metalloproteinase inhibitor 4; TLT-2 = Trem-like transcript 2 protein; TNF-R1 = Tumor necrosis factor receptor 1; TNF-R2 = Tumor necrosis factor receptor 2; 
TNFRSF10C = Tumor necrosis factor receptor superfamily member 10C; TNFRSF14 = Tumor necrosis factor receptor superfamily member 14; TNFSF13B = 
Tumor necrosis factor ligand superfamily member 13B; t-PA = Tissue-type plasminogen activator; TR = Trassferrin receptor protein 1; TR-AP = Tartrate-
resistant acid phosphatase type 5; uPA = Urokinase-type plasminogen activator; U-PAR = Urokinase plasminogen activator surface receptor; vWF; von 
Willebrand factor 
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Supplementary Table 2; Hazard ratio for tertiles of Waist-hip ratio in different HF subgroups and all-
cause mortality 
 
All-cause mortality 
HFrEF Hazard ratio° P-value Hazard ratio* P-value 
Waist-hip ratio 1st tertile Ref  Ref  
Waist-hip ratio 2nd tertile 
1.27 
[0.90-1.79] 0.181 
0.92 
[0.63-1.34] 0.654 
Waist-hip ratio 3rd tertile 
1.64 
[1.19-2.26] 0.002 
1.34 
[0.95-1.89] 0.099 
All-cause mortality 
HFmrEF Hazard ratio° P-value Hazard ratio* P-value 
Waist-hip ratio 1st tertile Ref  Ref  
Waist-hip ratio 2nd tertile 
0.89  
[0.56-1.40] 0.613 
0.93  
[0.58-1.49] 0.753 
Waist-hip ratio 3rd tertile 
1.33 
[0.85-2.06] 0.210 
1.41 
[0.87-2.26] 0.162 
All-cause mortality 
HFpEF Hazard ratio° P-value Hazard ratio* P-value 
Waist-hip ratio 1st tertile Ref  Ref  
Waist-hip ratio 2nd tertile 
1.25  
[0.81-1.94] 0.322 
1.46  
[0.91-2.34] 0.120 
Waist-hip ratio 3rd tertile 
1.47 
[0.96-2.24] 0.076 
2.08 
[1.30-3.33] 0.002 
 
° Univariable model 
* All are corrected for age, sex, Urea, NT-proBNP, hemoglobin, use of beta-blocker and statins 
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Supplementary Figure 1; Histogram of distribution of WHR in the total population (left), in women 
(middle) and in men (right).  
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Supplementary Figure 2; Hazard ratio for Waist-hip ratio separated for women (left) and men (right) in 
HFrEF , HFmrEF and HFpEF . Corrected for age, Urea, NT-proBNP, hemoglobin, use of beta-blocker 
and statins 
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Supplementary Figure 3; Hazard ratio for Waist and Hip circumference in women (top) and men 
(bottom).  
 
 
